Clovis Oncology Inc  

(Public, NASDAQ:CLVS)   Watch this stock  
77.86
0.00 (0.00%)
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 39.45 - 102.28
Open     -
Vol / Avg. 0.00/585,056.00
Mkt cap 2.97B
P/E     -
Div/yield     -
EPS -6.74
Shares 37.59M
Beta 2.00
Inst. own 95%
Nov 4, 2015
Q3 2015 Clovis Oncology Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 6, 2015
Q2 2015 Clovis Oncology Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Clovis Oncology Inc Earnings Release
Jun 11, 2015
Clovis Oncology Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -1174.54%
Operating margin - -1163.00%
EBITD margin - -1062.21%
Return on average assets -41.95% -22.29%
Return on average equity -126.88% -38.58%
Employees 136 -
CDP Score - -

Address

2525 28th St Unit 100
BOULDER, CO 80301-1255
United States - Map
+1-303-6255000 (Phone)
+1-303-2450360 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Patrick J. Mahaffy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Erle T. Mast Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Gillian C. Ivers-Read Executive Vice President - Technical Operations, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Lindsey Rolfe Chief Medical Officer, Executive Vice President - Clinical and Preclinical Development & Pharmacovigilance
Bio & Compensation  - Reuters
Steven L. Hoerter Senior Vice President - Commercial
Age: 44
Bio & Compensation  - Reuters
Brian G. Atwood Independent Director
Age: 62
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 59
Bio & Compensation  - Reuters